Patients who have had an acute coronary syndrome (ACS) event have an increased risk for depression.
H
eart disease is the leading cause of death in the United States and worldwide (1, 2) , and according to estimates, more than 1 million Americans are hospitalized for an acute coronary syndrome (ACS) event each year (3) . Patients in whom ACS is diagnosed are at risk for a range of negative physical and mental health outcomes, including elevated symptoms of depression and major depressive disorder (MDD) (4). In the general population, the 12-month prevalence of MDD is approximately 7% (5), but studies have found that as many as 20% of post-ACS patients have MDD and 65% of post-myocardial infarction (MI) patients have elevated depression symptoms (6 -8). Depressive disorders are estimated as the second largest cause of loss in disability-adjusted life-years (9), and patients with depression after an ACS event have a substantially increased risk for death (10, 11) .
Despite the link between depression and poor outcomes in patients after an ACS event, considerable uncertainty exists regarding whether and how to screen post-ACS patients for depression (12) . Guidelines for depression screening in primary care settings vary. The 2016 guidelines from the U.S. Preventive Services Task Force recommend that depression screening for the general population in primary care be "implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow up" (13). However, other guidelines recommend targeted screening for patients at increased risk for depression (14) or advise against routine screening (15). After an ACS event, persons are at greater risk for depression, and some professional societies recommend routine screening during and after the post-MI hospitalization; however, these guidelines are controversial (16, 17) . It is unclear how well standard instruments for detecting depression perform in this medically ill group and whether this group would benefit from targeted screening.
Also unclear is whether post-ACS patients with depression and persons in the general population with depression respond any differently to commonly used, empirically validated treatments for depression. Such treatments include pharmacotherapy and psychotherapy (10), with second-generation antidepressants and 
Data Sources and Study Selection
In consultation with an expert medical librarian, we searched MEDLINE (via PubMed), EMBASE, PsycINFO, CINAHL, and the Cochrane Database of Systematic Reviews from January 2003 through August 2017. Appendix Table 1 (available at Annals.org) contains our search strategies. We also searched ClinicalTrials.gov for relevant completed and ongoing studies, manually searched review articles and primary sources to identify studies, and notified stakeholders of interest in relevant gray literature.
Our prespecified inclusion and exclusion criteria are provided in Appendix Table 2 (available at Annals .org). For our first key question, we included Englishlanguage observational studies with at least 50 participants that examined the diagnostic accuracy of depression screening instruments compared with a validated criterion standard (such as the Diagnostic and Statistical Manual of Mental Disorders or International Classification of Diseases criterion-based clinical interview) in adults within 3 months of an identifying ACS event. For our second key question, we included English-language randomized clinical trials with at least 20 participants that compared the safety and effectiveness of a wide range of depression treatment interventions (namely, antidepressant medication, psychotherapy, enhanced care delivery, and other treatments) with an active comparator or usual care and included at least 6 weeks of follow-up in adults with depression who were within 3 months of an ACS event. The 3-month post-ACS criterion for both key questions was selected for consistency with the 2005 AHRQ report and to identify a population that could be distinguished from patients with coronary heart disease. Our stakeholders and technical expert panel provided guidance on outcome selection.
Data Extraction and Quality Assessment of Individual Studies
Pairs of investigators screened all citations and abstracts for eligibility, and those considered relevant by either investigator advanced to full-text review. Investigator pairs then reviewed all full-text articles and resolved disagreements through discussion with or adjudication by a third investigator. Paired investigators independently assessed study quality and resolved disagreements by consensus or arbitration by a third investigator. The methodological quality, or risk of bias, of each study was assessed by using the Cochrane Risk of Bias Tool (23) for clinical trials and QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies, revised) (24) for observational studies.
For each included study, an investigator abstracted data using a customized DistillerSR database (Evidence Partners); a second investigator independently reviewed these data for accuracy. Relevant data included details of the screening approach (such as instrument version and administration mode), details of the treatment (such as pharmacotherapy dosing, behavioral intervention methods, and co-interventions), patient characteristics that may be related to outcomes (such as depressive disorder, age, and sex), clinical settings (such as primary care and inpatient), diagnostic accuracy of screening instruments (such as sensitivity, specificity, negative predictive value [NPV] , and positive predictive value [PPV]), and clinical treatment outcomes (such as total mortality, depression-related outcomes, cardiac-related outcomes, quality of life, and adverse effects). In addition, we described comparators carefully, because treatment standards may have changed during the period covered by the review. The safety outcomes were framed to help identify adverse events, including those from drug therapies and those resulting from misdiagnosis or labeling. We contacted manuscript authors if important data were missing or unclear in the published article.
Data Synthesis
We reviewed the quality of included studies to determine whether differential consideration was merited, and then we determined the feasibility of completing quantitative syntheses (that is, meta-analyses). Feasibility depended on the volume of relevant literature (we required 3 appropriate studies to consider metaanalysis), conceptual homogeneity of the studies, and completeness of results reporting. When a metaanalysis was appropriate, we used random-effects models (DerSimonian-Laird estimator with KnappHartung SE adjustment) to synthesize the available evidence quantitatively. For our key question on depression screening, proportions were summarized on the logit (log odds) scale and then converted back to a proportion. Individual study sensitivities and specificities were calculated with exact 95% CIs. Sensitivities and specificities were summarized separately as proportions, because a joint model, which would have summarized these together, did not converge.
For our key question on depression treatment, we anticipated that intervention effects may be heterogeneous. We hypothesized that the methodological quality of individual studies, the study type, the characteristics of the comparator, and patients' underlying clinical presentation were associated with the intervention effects. We planned subgroup and metaregression analyses to examine these hypotheses, but quantitative analyses were not feasible because of the small number of studies with diverse comparisons.
We conducted meta-analysis with the R statistical package, version 3.1.2 (The R Foundation), using the "metaphor" package (version 1.9-7).
Strength of Evidence
We assessed the strength of evidence (SOE) by using the approach described in the AHRQ Methods Guide (25, 26). We assessed 5 domains: study limitations (previously named risk of bias); consistency; directness; precision; and reporting bias, which includes publication bias, outcome reporting, and analysis reporting bias. For intervention trials, these domains affect the confidence in treatment effects. For diagnostic test studies, these factors affect the confidence in estimates of test accuracy and effects on patient management (27). These domains were considered qualitatively, and a summary rating of high, moderate, or low SOE was assigned for each outcome after independent Threshold considered optimal by authors Version >10 = 0.07 PHQ-10 >5 Threshold considered optimal by authors assessment and then discussion by 2 reviewers. In cases in which ratings were impossible or imprudent, a grade of "insufficient" was assigned.
Role of the Funding Source
This topic was nominated by the American Academy of Family Physicians (AAFP) and selected by AHRQ for systematic review by an Evidence-based Practice Center. A representative from AHRQ served as a contracting officer's representative and provided technical assistance during the conduct of the full evidence report and comments on draft versions of the full evidence report. The agency did not directly participate in the literature search; determination of study eligibility criteria; data analysis or interpretation; or preparation, review, or approval of the manuscript for publication.
RESULTS
From 2481 screened citations, 204 full-text articles were reviewed and 21 articles representing 10 eligible studies were identified: 6 relevant to depression screening and 4 to treatment (Figure 1) . Table 1 provides summary characteristics of the included studies, with individual characteristics for screening and treatment studies provided in Appendix Tables 3 and 4 (available at Annals.org), respectively. We located publications for all relevant completed trials identified by searching ClinicalTrials.gov, thus finding no indication of publication bias.
Depression Screening in Post-ACS Patients
We identified 7 articles (28 -34) representing 6 observational studies with a total of 1763 prospectively enrolled (1755 completed) patients that evaluated the accuracy of depression screening instruments in post-ACS patients. Major depressive disorder served as the criterion standard for studies, with 1 study (34) describing the criterion standard as "clinical depression" according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (correspondence with the authors indicated that most of these patients had MDD, although some had minor depression). Three studies compared 2 instruments head to head, such that the Beck Depression Inventory-II (BDI-II) was evaluated in 4 studies (29, 30, 32, 33), the Hospital Anxiety and Depression Scale (HADS) in 3 studies (28 -30), the Geriatric Depression Scale (GDS) in 1 study (33), and the Patient Health Questionnaire Two studies had sample sizes greater than 500 (29, 30), each of which included at least 50 patients with an MDD diagnosis; the remaining 4 studies had sample sizes ranging from 79 to 131 and MDD diagnoses in 27 or fewer patients. Rates of MDD prevalence were within 3 percentage points of 10% in 4 of the included studies (29 -33), whereas 1 study of "clinical depression" (which included some patients with minor depression, according to correspondence with the authors) found a rate of 23% (34) and 1 poor-quality study had a rate of 34% (28). One study focused exclusively on post-MI patients (31, 32), and the remaining 5 studies of post-ACS patients had samples in which post-MI patients constituted approximately 30% to 70% of the total. Table 2 provides information on the included studies and diagnostic accuracy of the screening tools considered.
BDI-II
All 4 studies using the BDI-II examined the generally accepted cutoff score of 14 or more points, with corresponding sensitivity ranging from 83% to 91% and specificity from 74% to 88%. A meta-analysis of these 4 studies using this traditional cutoff indicated an overall sensitivity of 90% (95% CI, 86% to 92%) and specificity of 80% (CI, 68% to 88%) ( Figure 2) . Three of these studies reported PPV and NPV, with PPV ranging from 28% to 46% and NPV from 98% to 99%. Optimal cutoffs for depression screening among post-ACS patients varied in the 3 studies that examined this value (29, 31-33), indicating optimal cutoff scores of 10, 14, and 16 points. One study of 131 post-ACS patients (32) found that using the 1 sadness item alone from the BDI-II (score ≥0 point on a single item), or the sadness item plus the anhedonia item from the BDI-II (2 items total), resulted in screening test values similar to those produced from using the full 21-item BDI-II with a threshold of 14 or more points (31).
HADS
Summarizing findings from studies examining the HADS was complicated by the studies' divergent approaches to evaluating this measure: 1 study examined the full HADS and reported only enough information to allow calculation of PPV (28); 1 examined only the HADS anxiety subscale (HADS-A) along with the BDI-II (30); and 1 examined the full HADS, the HADS-A, and the HADS depression subscale (HADS-D) along with the BDI-II (29). For the HADS and its subscales at traditional and optimal cutoffs, reported sensitivity ranged from 41% to 86%, specificity from 62% to 90%, PPV from 23% to 34%, and NPV from 93% to 98%. In the 1 study that examined the HADS-D (29), this subscale slightly underperformed the full HADS, HADS-A, and BDI-II. Of the 2 studies that examined both the HADS-A (threshold of ≥8 points) and BDI-II (threshold of ≥14 points), 1 found the scales to perform similarly (29) and the other found the HADS-A to not perform as well as the BDI-II (30).
Other Screening Instruments
One study compared the 30-item GDS with the BDI-II and found the GDS to have similar sensitivity but somewhat better specificity and PPV (33). A threshold of 10 or more points for the GDS was considered optimal for the post-ACS population, as opposed to the traditional 14 or more points. Another study examined the PHQ, evaluating the 2-item (threshold, >0 point), 9-item (threshold, >4 points), and 10-item (threshold, >5 points) versions (34). All versions demonstrated excellent area-under-the-curve statistics (91% to 93%) and had similar sensitivity (96% to 97%) and specificity (71% to 78%).
Study Quality and SOE
Risk of bias generally was assessed as low across the 6 studies, with a rating of high risk being applied to 1 study for patient selection (28), no study for index tests, 1 study for reference standard (32), and 1 study for flow and timing (28) (Appendix Table 6 , available at Annals.org). The BDI-II is the only tool with sufficient evidence to support SOE ratings (Appendix Table 7 , available at Annals.org).
Depression Treatment in Post-ACS Patients
We identified 14 articles (35-48) representing 4 randomized controlled trials (36, 39, 40, 46) involving a total of 3119 post-ACS patients that compared pharmacologic and nonpharmacologic treatments and enhanced care delivery approaches with usual care in terms of safety and effectiveness in treating depression. We identified no studies evaluating nutritional supplements, aerobic exercise, cardiac rehabilitation, stress management, atypical antipsychotic medications, transcranial magnetic stimulation, or electroconvulsive therapy. Three studies were conducted solely in the United States (36, 39, 40), and 1 was carried out in the United Kingdom and Europe (46). No study reported intervention effects on stroke, gastrointestinal bleeding, emergency department visits, suicidality, or costeffectiveness. Three of the 4 studies were rated as good quality (36, 39, 40), and 1 was rated as fair quality (46). Studies were too few and interventions too diverse for quantitative analysis.
Enhanced Care
Two trials-CODIACS (Comparison of Depression Interventions After Acute Coronary Syndrome) (39) and COPES (Coronary Patients Evaluation Study) (40)-compared enhanced care with usual care in a total of 307 post-ACS patients with persistent depression symptoms. In CODIACS, enhanced care included 6 months of centralized, team-based care with patient preference-based treatments (antidepressant therapy, psychotherapy, or both) and routine monitoring with escalation of care as needed for nonresponse (stepped care). Enhanced care in COPES was based on a collab-orative care model, which was provided by a team including a clinical nurse specialist, psychologist, and social worker or psychiatrist, and offered preferencebased treatments to patients.
At 6-month follow-up in the CODIACS study, compared with patients receiving usual care, those in the enhanced-care group had a greater decrease in depression symptoms (a difference of Ϫ3.5 [CI, Ϫ6.1 to Ϫ0.7] points in BDI score) and a greater depression remission rate (BDI score <10 points; relative risk, 1.7 [CI, 1.04 to 2.40]) but no difference in depression response (>0.05-SD improvement in BDI score), mental health-related functioning, total health care costs, rates of hospitalization for any cause, or revascularization. In COPES, patients receiving enhanced care had a greater decrease in depression symptoms than those receiving usual care at 9-month follow-up (difference of Ϫ3.8 [CI, Ϫ6.5 to Ϫ1.2] points in BDI score).
Sequenced CBT and Antidepressants
One trial, ENRICHD (Enhancing Recovery in Coronary Heart Disease) (36), examined a sequenced strategy of CBT and antidepressant therapy compared with usual care in a sample of 2481 post-MI patients with MDD (52%), minor depression or dysthymia (20%), or low perceived social support. Patients receiving the intervention demonstrated a statistically significantly greater decrease in depression symptoms at 6 months than those receiving usual care (difference, Ϫ2.7 [CI, Ϫ3.7 to Ϫ1.7] points in BDI score and Ϫ1.7 [CI, Ϫ2.5 to Ϫ0.9] points on the Hamilton Rating Scale for Depression). At the end of the intervention, patients in the treatment group reported statistically significantly greater mental health-related functioning (2.2 [CI, 1.2 to 3.2] points higher on the Short Form-12 Health Survey) and overall life satisfaction (1 point [CI, 0.5 to 1.5 points] higher on the Life Satisfaction Scale), with no between-group differences in physical health-related functioning, major cardiac events (hazard ratio 
Antidepressants
One trial, MIND-IT (Myocardial Infarction and Depression-Intervention Trial) (46), compared antidepressant treatment with usual care during a 6-month course in 331 post-MI patients with MDD. Patients in the intervention group were offered first-line treatment with mirtazapine, followed by citalopram as second-line therapy, and personalized antidepressant treatment by a psychiatrist as third-line treatment. At 18-month follow-up, no statistically significant between-group differences were seen in depression symptoms, physical or mental health symptoms, disability, quality of life, rate of major cardiac events, or event rates for specific cardiac outcomes (such as myocardial ischemia). Table 3 summarizes the overall SOE regarding depression treatments in post-ACS patients. In general, the SOE was stronger for depression than cardiovascular outcomes and stronger for CBT with antidepressants than for other interventions. A common limitation across all comparisons was the small number of studies. For enhanced care and antidepressant medication, the small number of patients enrolled and relatively few cardiovascular events led to imprecise estimates and lower SOE. Appendix Table 8 (available at Annals.org) summarizes risk of bias, which generally was low.
Study Quality and SOE

DISCUSSION
Heart disease and depression are among the leading causes of loss in disability-adjusted life-years (9, 49), with ACS events increasing the risk for depression (4) and depression increasing the risk for death among post-ACS patients (10, 11). Effectively identifying and treating depression among post-ACS patients is a clinical and public health priority. This systematic review sought to evaluate the diagnostic accuracy of depression screening tools and the safety and effectiveness of depression treatments in post-ACS patients. Available evidence indicates that the diagnostic accuracy metrics of depression screening tools are similar in post-ACS and other clinical populations and that evidence-based Post-ACS Depression REVIEW depression interventions are moderately effective in improving mental health symptoms, although there is no indication yet that these interventions improve cardiovascular outcomes or longevity.
The 21-item BDI-II, the most frequently examined tool in the depression screening studies, displayed acceptable levels of sensitivity, specificity, and NPV (PPV was low). Two studies examined much briefer approaches to screening-one examining 1 or 2 select items from the BDI-II and the other examining the 2-, 9-, and 10-item versions of the PHQ-and both found diagnostic accuracy metrics generally consistent with those produced by using longer screeners. This finding merits further research, because such brief screening tools would clearly embody efficiencies in clinical settings and might encourage broader uptake of screening practices.
In the 4 trials that evaluated depression treatment in post-ACS patients, improvement in depressive symptoms was statistically significant in 3 of the studies but of relatively little clinical significance. This was observed when comparing usual care with either enhanced, team-based care that allowed for antidepressant therapy, psychotherapy, or both or sequenced CBT and antidepressant therapy. Adverse effects were not well-reported in these studies.
Findings with respect to depression screening and treatment among post-ACS patients are generally consistent with existing practice guidelines. Both the 2008 American Heart Association (17) and 2009 AAFP clinical practice guidelines (16) recommend screening for depression in post-MI patients at regular intervals, including during the initial hospitalization (level A). As for treatment, the AAFP recommends that patients "post-MI with a diagnosis of depression" be treated "with systems in place to ensure regular follow-up and monitoring of their treatment response and adherence to treatment" (level A), with selective serotonin reuptake inhibitors preferred over tricyclic antidepressants (level A), and suggests that psychotherapy also may be beneficial (level B) (16). On the basis of the limited literature considered in our systematic review on depression treatment in post-ACS patients, evidence-based psychotherapies, such as CBT (alone, as part of enhanced care, or in combination with second-generation antidepressants), were an important element of the treatment approaches that demonstrated effectiveness.
Our systematic review updates the 2005 AHRQ publication on depression in patients after MI (22) by expanding it to consider post-ACS patients and narrowing in on the topics of screening and treatment. We identified 5 studies, in addition to the 1 in the 2005 report, that compared screening measures with a criterion standard. Concern regarding low PPV rates also was expressed in the 2005 review. The 2005 report concluded that selective serotonin reuptake inhibitors improved depression compared with placebo. In the present review, we found evidence supporting the effectiveness of psychotherapies, such as CBT, and structured models of enhanced care. As in 2005, evidence that effective treatment for depression increases survival is still lacking, although more sufficiently powered longitudinal studies are needed. Results of the present review also are generally consistent with those of a recently published, more inclusive review examining psychological interventions for coronary heart disease, which found some evidence that interventions alleviated psychological symptoms and reduced cardiac mortality while demonstrating no statistically significant risk reduction in total mortality, revascularization procedures, or nonfatal MI (50).
The current review has several limitations. First, we considered only literature published after the 2005 AHRQ report's cutoff date (March 2004) and examined only studies published in English. Second, we did not directly evaluate the effectiveness of screening, which ideally would be assessed by randomized controlled trials comparing the effects of screening with those of no screening on depression and cardiovascular outcomes. Third, we examined characteristics of screening tools as related only to depression, although some instruments, such as the HADS, also assess for anxiety. Finally, the evidence base is limited. More trials investigating other screening tools (such as the commonly used PHQ) and brief screens are desirable. Additional treatment studies also are greatly needed, because the current review was confined to only 4, not all of which were sufficiently powered to examine cardiovascular outcomes.
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